Merck chases Bayer/Ionis with fast track for Factor XI drug

The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for people with end-stage renal disease (ESRD) who need dialysis, firing a warning short

Ionis antithrombotic with reduced bleed risk clears phase 2b...

Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to prevent blood clots, but as a result, can experience bleeding side effects.

FDA fast tracks Bayer's oral anticoagulant asundexian

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

CHMP backs safety of anticoagulants after real-world study

AI-powered study backs anticoagulants for heart failure pati...

A new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of whether they already have atrial fibrillation (AF).

Portola's anticoagulant antidote gets EU review

Portola has said European regulators are to review its anticoagulant antidote, IndexXa (andexanet alfa), just days after the US regulator rejected the drug.